【摘要】 目的:评价齐拉西酮治疗精神分裂症的疗效。方法:60例精神分裂症患者,随机分为齐拉西酮组和利培酮组,每组30例,分别给予齐拉西酮和利培酮治疗,疗程均8周。采用阳性与阴性症状量表(PANSS)评定疗效;以治疗中出现的症状量表(TESS)和锥体外系反应量表(RSESE)评定不良反应。结果:治疗后两组PANSS总分及各因子分均较治疗前显著下降(P<0.05或P<0.01)。齐拉西酮组锥体外系反应(EPS)发生率26.3%明显低于利培酮组53.3%(χ2=4.44,P<0.05)。结论:齐拉西酮与利培酮治疗精神分裂症疗效相当,齐拉西酮为安全有效的抗精神病药。更多还原

【Abstract】 Objective:To evaluate the efficacy of ziprasidone hydrochioride in the treatment of schizophrenia.Method:Sixty inpatients with schizophrenia were randomly divided into ziprasidone hydrochioride group(n=30) and resperidone group(n=30) for 8 weeks.Both groups were assessed with the positive and negative symptoms scale(PANSS),treatment emergent symptoms scale(TESS)and rating scale for extrayramidal side effects(RSESE) to evaluate their efficacy and side reactions.Results:Two drugs had similar efficacy in the treatment of schizophrenia.The occurrence rate of EPS in ziprasidone hydrochioride group was 26.3%,which was significantly lower than that of resperidone group 53.3%(χ2=4.44,P<0.05).Conclusion:Ziprasidone hydrochioride is an effective and safe antipsychotic drug.更多还原